These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 6491697

  • 1. Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma.
    O'Connell MJ, Moertel CG, Rubin J, Hahn RG, Kvols LK, Schutt AJ.
    J Clin Oncol; 1984 Oct; 2(10):1133-8. PubMed ID: 6491697
    [Abstract] [Full Text] [Related]

  • 2. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
    Buroker TR, Moertel CG, Fleming TR, Everson LK, Cullinan SA, Krook JE, Mailliard JA, Marschke RF, Klaassen DJ, Laurie JA.
    J Clin Oncol; 1985 Dec; 3(12):1624-31. PubMed ID: 2933492
    [Abstract] [Full Text] [Related]

  • 3. Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
    Chiuten DF, Valdivieso M, Bedikian A, Bodey GP, Freireich EJ.
    Cancer Treat Rep; 1985 Jun; 69(6):611-3. PubMed ID: 4016768
    [Abstract] [Full Text] [Related]

  • 4. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
    Ardalan B, Singh G, Silberman H.
    J Clin Oncol; 1988 Jun; 6(6):1053-8. PubMed ID: 3373260
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
    O'Dwyer PJ, Paul AR, Walczak J, Weiner LM, Litwin S, Comis RL.
    J Clin Oncol; 1990 Sep; 8(9):1497-503. PubMed ID: 2391557
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
    O'Dwyer PJ, Hudes GR, Colofiore J, Walczak J, Hoffman J, LaCreta FP, Comis RL, Martin DS, Ozols RF.
    J Natl Cancer Inst; 1991 Sep 04; 83(17):1235-40. PubMed ID: 1714507
    [Abstract] [Full Text] [Related]

  • 12. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
    Erlichman C, Donehower RC, Speyer JL, Klecker R, Chabner BA.
    J Natl Cancer Inst; 1982 Feb 04; 68(2):227-31. PubMed ID: 6950156
    [Abstract] [Full Text] [Related]

  • 13. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.
    Köhne CH, Harstrick A, Hiddemann W, Schöffski P, Wilke H, Bokemeyer C, Dörken B, Schmoll HJ.
    Eur J Cancer; 1997 Oct 04; 33(11):1896-9. PubMed ID: 9470854
    [Abstract] [Full Text] [Related]

  • 14. Chemotherapy for colorectal cancer with a combination of PALA and 5-FU.
    Bedikian AY, Stroehlein JR, Karlin DA, Bennetts RW, Bodey GP, Valdivieso M.
    Cancer Treat Rep; 1981 Oct 04; 65(9-10):747-53. PubMed ID: 7273010
    [Abstract] [Full Text] [Related]

  • 15. Continuous five-day infusion of PALA and 5FU: a pilot phase II trial.
    Presant CA, Ardalan B, Multhauf P, Chan C, Staples R, Green L, Browning S, Carr BI, Chang FF, Thayer W.
    Med Pediatr Oncol; 1983 Oct 04; 11(3):162-3. PubMed ID: 6222250
    [Abstract] [Full Text] [Related]

  • 16. Effects of PALA on the pharmacokinetics of 5-fluorouracil.
    Nassim MA, Rouini MR, Cripps MC, Shirazi FH, Veerasinghan S, Molepo JM, Obrocea M, Redmond D, Bates S, Fry D, Stewart DJ, Goel R.
    Oncol Rep; 1998 Oct 04; 5(1):217-21. PubMed ID: 9458325
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
    Rosvold E, Schilder R, Walczak J, DiFino SM, Flynn PJ, Banerjee TK, Heim WJ, Engstrom PF, Ozols RF, O'Dwyer PJ.
    Cancer Chemother Pharmacol; 1992 Oct 04; 29(4):305-8. PubMed ID: 1537077
    [Abstract] [Full Text] [Related]

  • 18. Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
    Royce ME, McGarry W, Bready B, Dakhil SR, Belt RJ, Goodwin JW, Gray R, Hoff PM, Winn R, Pazdur R.
    J Clin Oncol; 1999 Oct 04; 17(10):3276-82. PubMed ID: 10506630
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.
    Langer CJ, Schaebler D, Sauter E, DeMaria D, Johnson C, Reilly DM, Clark J, Leighton J, Aks C, Litwin S, Ridge JA.
    Head Neck; 1998 Aug 04; 20(5):385-91. PubMed ID: 9663665
    [Abstract] [Full Text] [Related]

  • 20. Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
    Kemeny N, Conti JA, Seiter K, Niedzwiecki D, Botet J, Martin D, Costa P, Wiseberg J, McCulloch W.
    J Clin Oncol; 1992 May 04; 10(5):747-52. PubMed ID: 1569447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.